<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711410835</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711410835</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Blood pressure</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific papers</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Adding a low-dose antihypertensive regimen would substantially improve the control of hypertension and reduce cardiovascular morbidity among uncomplicated hypertensive patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ahola</surname><given-names>Teemu L</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711410835">1</xref>
<xref ref-type="aff" rid="aff2-1741826711410835">2</xref>
<xref ref-type="corresp" rid="corresp1-1741826711410835"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kantola</surname><given-names>Ilkka M</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711410835">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mäki</surname><given-names>Juhani</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711410835">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Reunanen</surname><given-names>Antti</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711410835">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jula</surname><given-names>Antti M</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711410835">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1741826711410835"><label>1</label>National Institute for Health and Welfare, Department of Chronic Disease Prevention, Turku/Helsinki, Finland.</aff>
<aff id="aff2-1741826711410835"><label>2</label>Turku University Central Hospital, Department of Internal Medicine, Turku, Finland.</aff>
<author-notes>
<corresp id="corresp1-1741826711410835">Teemu L Ahola, National Institute for Health and Welfare, Peltolantie 3, 20720 Turku, Finland Email: <email>teemu.ahola@pp3.inet.fi</email>, <email>teemu.ahola@thl.fi</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>4</issue>
<fpage>712</fpage>
<lpage>722</lpage>
<history>
<date date-type="received"><day>17</day><month>10</month><year>2010</year></date>
<date date-type="accepted"><day>27</day><month>4</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Aims:</bold> To assess the utilization of antihypertensive drugs among uncomplicated hypertensive patients in Finland between 2000 and 2006 and to calculate the achievable reduction in cardiovascular morbidity, with intensified antihypertensive treatment. <bold>Methods:</bold> From the databases of the Social Insurance Institution of Finland, 428,986 treated hypertensives without diabetes or cardiac disease (further named uncomplicated hypertensives) in 2000 and 591,206 in 2006, respectively, were identified. In addition, from the Health 2000 survey representing the whole Finnish adult population, 729 uncomplicated hypertensives were determined to assess their characteristics and control of hypertension. Applying Law′s meta-analyses we calculated the reduction of blood pressure (BP) by intensifying the treatment with low-dose antihypertensive regimens for those with a BP ≥140/90 mmHg. <bold>Results:</bold> The nationwide data suggests a relative overuse of beta-blockers. Combination antihypertensive treatment increased relatively 8%, while at least three drug combinations increased from 19.8% to 21.6% between 2000 and 2006. However, calculated prevalence of controlled BP (&lt;140/90 mmHg) increased only from 30.3% to 33.9%. Addition of one half standard dose or one to two half standard doses for the treatment of the patients with a BP ≥140/90 mmHg would improve the control of hypertension from 33.9% to 47.8% and 67.3%, respectively. The intensified treatment would reduce strokes by 18% and 28%, and ischaemic heart disease events by 13% and 21%, respectively. <bold>Conclusions:</bold> Underutilization of preferred drugs and poor control of BP continues. Surprisingly small addition of the number of low-dose antihypertensive regimen is needed in order to substantially improve the control of hypertension and to decrease cardiovascular morbidity among uncomplicated hypertensive patients.</p>
</abstract>
<kwd-group>
<kwd>Blood pressure</kwd>
<kwd>cardiovascular morbidity</kwd>
<kwd>combination therapy</kwd>
<kwd>drug therapy</kwd>
<kwd>hypertension</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711410835" sec-type="intro"><title>Introduction</title>
<p>Lowering systolic BP by 10 mmHg or diastolic BP by 5 mmHg reduces events of stroke by approximately one-third and of ischaemic heart disease (IHD) by approximately 20–25%.<sup><xref ref-type="bibr" rid="bibr1-1741826711410835">1</xref></sup><sup>−</sup><sup><xref ref-type="bibr" rid="bibr4-1741826711410835">4</xref></sup> While some drugs and drug combinations may be more effective in reducing cardiovascular morbidity, no category of drugs appears to be systematically inferior in their ability to reduce BP.<sup><xref ref-type="bibr" rid="bibr5-1741826711410835">5</xref></sup><sup>−</sup><sup><xref ref-type="bibr" rid="bibr8-1741826711410835">8</xref></sup> According to national and international guidelines, each agent can be preferentially prescribed under specific conditions.<sup><xref ref-type="bibr" rid="bibr9-1741826711410835">9</xref></sup> However, combination therapy is usually required to achieve a proper control of BP.<sup><xref ref-type="bibr" rid="bibr7-1741826711410835">7</xref></sup></p>
<p>Antihypertensive drugs are underused, and control of hypertension is poor both in Finland<sup><xref ref-type="bibr" rid="bibr10-1741826711410835">10</xref></sup> and other countries.<sup><xref ref-type="bibr" rid="bibr11-1741826711410835">11</xref></sup><sup>−</sup><sup><xref ref-type="bibr" rid="bibr13-1741826711410835">13</xref></sup> Among high-risk hypertensive patients, beta-blockers are used more frequently than other antihypertensive agents in Finland.<sup><xref ref-type="bibr" rid="bibr14-1741826711410835">14</xref>,<xref ref-type="bibr" rid="bibr15-1741826711410835">15</xref></sup> Whether this is also the case among Finnish uncomplicated hypertensives (i.e. hypertensive patients without diabetes, coronary heart disease (CHD), cardiac arrhythmias, or chronic heart failure (CHF)) with no specific indications for the use of beta-blockers is unknown. Furthermore, no nationwide longitudinal studies have been published on the use of different antihypertensive drug combinations (including three or more antihypertensive drugs) among uncomplicated hypertensive patients.</p>
<p>The main purpose of this study was to assess the utilization of antihypertensive drugs and drug combinations in 2000 and 2006 among adult, treated, uncomplicated hypertensive patients in Finland and to estimate the effects of the observed changes in blood pressure control and cardiovascular morbidity. Moreover, we calculated the expected improvements in the control of hypertension and the expected reductions in cardiovascular morbidity if the treatment of uncontrolled hypertension would have been intensified by one to two half standard doses of ordinary BP-lowering drugs.</p>
</sec>
<sec id="sec2-1741826711410835" sec-type="methods"><title>Methods</title>
<sec id="sec3-1741826711410835"><title>Subjects of study</title>
<p>We used two databases; the database of the Social Insurance Institution (SII) and the data of the Health 2000 (H2000) survey, partly in parallel and partly complementary to each other, to evaluate the treatment and control of hypertension and dyslipidaemia among Finnish adult patients with uncomplicated hypertension (<xref ref-type="fig" rid="fig1-1741826711410835">Figure 1</xref>).
<fig id="fig1-1741826711410835" position="float"><label>Figure 1.</label><caption><p>Subject selection and classification. In the database of the Social Insurance Institution, there are two separate results. Figures concerning the time 6 years later are printed in italics. *Also including entitlement to reimbursement of antidiabetic medication costs in 2001. #Also including those with entitlement to reimbursement of antidiabetic medication costs in 2007. CHD, coronary heart disease; CHF, chronic heart failure.</p></caption><graphic xlink:href="10.1177_1741826711410835-fig1.tif"/></fig></p>
<sec id="sec4-1741826711410835"><title>The Health 2000 survey</title>
<p>The H2000 study was carried out in Finland in the period from late 2000 to early 2001.<sup><xref ref-type="bibr" rid="bibr16-1741826711410835">16</xref></sup> The population in the study was a two-stage stratified cluster sample (8028 persons) representing the whole Finnish population aged 30 years or over. The implementation of the survey, described in detail elsewhere,<sup><xref ref-type="bibr" rid="bibr16-1741826711410835">16</xref></sup> involved a home interview followed by a comprehensive health examination.</p>
<p>Persons who had not participated in the health examination, had incomplete laboratory data, had not completed questionnaires properly, or had not participated in two measurements of BP, were excluded from the study. Altogether 6209 subjects (77% of the sample) were included in the further analysis. Of these, 1416 subjects received antihypertensive medication and from them, accordingly, we excluded 687 subjects with diabetes, CHD, cardiac arrhythmias, or CHF. Thereby the remaining 729 subjects, who very likely used antihypertensive medication due to hypertension only, were included to represent uncomplicated hypertensive patients (<xref ref-type="fig" rid="fig1-1741826711410835">Figure 1</xref>).</p>
<p>Data of the H2000 study was used to assess treatment and control of hypertension, and to crossvalidate drug utilization data obtained from the large database of the Social Insurance Institution.</p>
</sec>
<sec id="sec5-1741826711410835"><title>The Social Insurance Institution database</title>
<p>From the database of the Social Insurance Institution (SII), 100% of the prescribed antihypertensive and lipid-lowering drugs purchased in Finland between 1 September to 30 November in 2000 and in 2006 were collected. We identified 669,936 individuals aged 30 years or over in 2000, and 880,654 in 2006, who used antihypertensive drugs. From these we excluded 240,950 patients with diabetes, CHD, cardiac arrhythmias, or CHF in 2000, and 289,448 in 2006.</p>
<p>The SII database was used to assess in detail the utilization of antihypertensive and lipid-lowering drugs among subjects with uncomplicated hypertension in 2000 and 2006, and, in addition, to crossvalidate data obtained from the H2000 survey.</p>
</sec>
</sec>
<sec id="sec6-1741826711410835"><title>Ethical assessments</title>
<p>The study protocol of H2000 study was approved by the Epidemiology Ethics Committee of the Helsinki and Uusimaa hospital region. All participants of the survey gave a signed informed consent.</p>
</sec>
<sec id="sec7-1741826711410835"><title>Definitions</title>
<sec id="sec8-1741826711410835"><title>The Health 2000 survey</title>
<p>The health examination involved fasting blood samples for biochemical tests, an electrocardiogram, measurements of BP, weight, and height, a health interview, and a structured physical examination carried out by centrally trained physicians. Definition of uncomplicated hypertension required a regular use of antihypertensive medication (beta-blockers, diuretics, antiadrenergic drugs, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) without presence of diabetes, CHD, cardiac arrhythmias, or CHF.</p>
<p>Diabetes mellitus was defined as a fasting serum glucose ≥7.0 mmol/l and/or a regular (history of the) use of antidiabetic drugs. Definition of CHD required at least one of the following: diagnosis of myocardial infarction (MI) and/or angina pectoris during the field examination; large Q-waves in electrocardiography at rest; hospitalization for CHD (ICD-8 or ICD-9 codes 410–414 or ICD-10 codes I20−I25); a history of coronary revascularization procedure; or having the right of drug costs reimbursements for CHD. Cardiac arrhythmias were defined by a documented history of undeniable cardiac arrhythmia, existence of cardiac pacemaker, or entitlement to reimbursement for cardiac arrhythmias medication costs conceded by SII. Chronic heart failure was defined by a documented history of congestive heart failure or a positive response to the medication for CHF. Definition of dyslipidaemia was based on the Finnish dyslipidaemia guidelines and required at least one of the following: a serum low-density lipoprotein cholesterol value more than 3.0 mmol/l; a serum triglyceride value more than 2.0 mmol/l; a serum high-density lipoprotein cholesterol value less than 1.0 mmol/l; or if the individual was already under lipid-lowering medication. Smokers were defined as those smoking daily.</p>
</sec>
<sec id="sec9-1741826711410835"><title>Database of the Social Insurance Institution (SII)</title>
<p>SII may grant the patient a special reimbursement, which covers 72% of the medication costs caused by CHD, cardiac arrhythmias, and CHF. In case of diabetes the respective coverage is 100%. In order to obtain the entitlement, a patient must fulfil diagnostic criteria of corresponding illness and submit a physician’s certification. In this data, patients with CHD, cardiac arrhythmias, and CHF, we defined as those entitled to reimbursement for the medication costs of these specific illnesses as conceded by the SII in 2000 and 2006, respectively. Entitlement to reimbursement for diabetes medication costs may be conceded not earlier than 6 months from the diagnosis of diabetes. Therefore, we defined diabetic patients as those entitled to reimbursement for antidiabetic medication costs during 2000 or 2001, and 2006 or 2007, respectively. As uncomplicated hypertensives, we defined those aged 30 years or more who had purchased prescribed BP-lowering medication (beta-blockers, diuretics, antiadrenergic drugs, CCBs, ACE inhibitors, or ARBs) and were not entitled to reimbursement for CHD, cardiac arrhythmias, CHF, or diabetes medication costs (<xref ref-type="fig" rid="fig1-1741826711410835">Figure 1</xref>). However, SII may also concede a reimbursement for hypertension medication costs. Depending on family history and other cardiovascular risk factors, the granting limit is 180–200 mmHg for systolic BP, and 95–105 mmHg for diastolic BP. Therefore, we divided hypertensive patients according to the existence of reimbursement for hypertension medication costs into moderately to severely hypertensives and mildly hypertensives (<xref ref-type="fig" rid="fig1-1741826711410835">Figure 1</xref>).</p>
<p>If a combination antihypertensive drug product was taken, the drug was included in both drug classes.</p>
</sec>
</sec>
<sec id="sec10-1741826711410835"><title>Assessment of control of hypertension</title>
<p>BP levels were measured only in H2000 study in the beginning of the 2000s. BP levels and control of hypertension in 2006 were calculated by linking H2000 study and the database data of SII together and taking into account changes in age, sex, and drug utilization (mean number of BP-lowering drugs) of the target population between late 2000 and late 2006. In addition, we applied Law’s meta-analyses,<sup><xref ref-type="bibr" rid="bibr2-1741826711410835">2</xref></sup> to calculate the expected reductions in BP levels with add-on therapy, when necessary, and to calculate the expected improvements in the control of hypertension of the target population. The treatment was intensified by adding one to two half standard doses (or one to two standard doses accordingly) only for those with a BP ≥140/90 mmHg. No drugs were added if a BP was already below 140/90 mmHg. The second drug was added only if the control of hypertension (BP &lt;140/90 mmHg) was not achieved with the first drug add-on therapy.</p>
</sec>
<sec id="sec11-1741826711410835"><title>Statistical analyses</title>
<p>Statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary, North Carolina, USA), taking population weighting into account. Comparisons between H2000 and SII database were made using one-group <italic>t</italic>-test where the database mean value was taken as a constant. Categorical variables were compared with a chi-square test where the database data was used to calculate the expected frequencies. The data from the databases of SII represent the whole population. Therefore, no statistical methods were used at the comparison of the database data. Data are reported as mean (SD) and/or percentages. A <italic>p</italic>-value &lt;0.05 was considered statistically significant. BP reductions as well as relative risk of stroke and ischaemic heart disease (IHD) events were calculated in resemblance to Law’s meta-analyses, recently published and described in detail elsewhere,<sup><xref ref-type="bibr" rid="bibr2-1741826711410835">2</xref></sup> taking into account pretreatment systolic and diastolic BP, age, number of drugs, and dose.</p>
</sec>
</sec>
<sec id="sec12-1741826711410835" sec-type="results"><title>Results</title>
<sec id="sec13-1741826711410835"><title>Characteristics of uncomplicated hypertensive patients</title>
<p>The characteristics of the uncomplicated hypertensive patients are described in <xref ref-type="table" rid="table1-1741826711410835">Table 1</xref>. Except for mean age and use of diuretics, there were no statistically significant differences between the results of H2000 and the SII database in 2000 (<xref ref-type="table" rid="table1-1741826711410835">Tables 1</xref> and <xref ref-type="table" rid="table2-1741826711410835">2</xref>).
<table-wrap id="table1-1741826711410835" position="float"><label>Table 1.</label><caption><p>Characteristics of the Finnish adult uncomplicated hypertensives according to the Health 2000 Survey and the database of Social Insurance Institution</p></caption>
<graphic alternate-form-of="table1-1741826711410835" xlink:href="10.1177_1741826711410835-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>1.2000–2001</th>
<th>2. 2000</th>
<th>3. 2006</th>
<th>1vs2</th>
<th>2vs3</th></tr>
<tr><th rowspan="3">Characteristic</th>
<th>H2000</th>
<th>Sll</th>
<th>Sll</th>
<th><italic>P</italic></th>
<th><italic>relative</italic></th></tr>
<tr><th>Hypertensives</th>
<th>Hypertensives</th>
<th>Hypertensives</th>
<th/>
<th><italic>change</italic></th></tr>
<tr><th>(n = 72S)</th>
<th>(n = 428 986)</th>
<th>(n = 591 206)</th>
<th/>
<th>%</th></tr></thead>
<tbody align="left">
<tr>
<td>Demographic</td>
<td/>
<td/>
<td/>
<td/>
<td/></tr>
<tr>
<td> Age, y</td>
<td>59.9(11.8)</td>
<td>62.2(13.4)</td>
<td>63.1(13.6)</td>
<td>&lt;0.001</td>
<td>+1</td></tr>
<tr>
<td> Female, %</td>
<td>62.5</td>
<td>61.1</td>
<td>60.1</td>
<td>NS</td>
<td>−2</td></tr>
<tr>
<td>Clinical</td>
<td/>
<td rowspan="12"/>
<td rowspan="12"/>
<td rowspan="12"/>
<td rowspan="12"/></tr>
<tr>
<td> Body mass index, kg/m<sup>2</sup> (<xref ref-type="table-fn" rid="table-fn2-1741826711410835">*</xref>n = 726)</td>
<td>29.0(5.0)</td></tr>
<tr>
<td> Waist-hip ratio (*n = 722)</td>
<td>0.92(0.08)</td></tr>
<tr>
<td> Systolic blood pressure, mmHg</td>
<td>146.1(20.6)</td></tr>
<tr>
<td> Diastolic blood pressure, mmHg</td>
<td>86.6(10.3)</td></tr>
<tr>
<td> Pulse pressure, mmHg</td>
<td>59.5(18.4)</td></tr>
<tr>
<td> Mean arterial pressure, mmHg</td>
<td>106.4(11.7)</td></tr>
<tr>
<td> Current smoker, %</td>
<td>15.4</td></tr>
<tr>
<td> Total cholesterol, mmol/l</td>
<td>6.1(1.1)</td></tr>
<tr>
<td> LDL-C, mmol/l (n = 706)</td>
<td>4.1(1.0)</td></tr>
<tr>
<td> HDL-C, mmol/l</td>
<td>1.3(0.4)</td></tr>
<tr>
<td> Triglycerides, mmol/l</td>
<td>1.8(1.1)</td></tr>
<tr>
<td> Number of antihypertensive drugs, n</td>
<td>1.7(0.83)</td>
<td>1.7(0.88)</td>
<td>1.8(0.92)</td>
<td>NS</td>
<td>+4</td></tr>
<tr>
<td> Combination antihypertensive treatment, %</td>
<td>47.1</td>
<td>50.4</td>
<td>54.2</td>
<td>NS</td>
<td>+8</td></tr>
<tr>
<td> Entitlement to reimbursements for hypertension</td>
<td rowspan="2">59.2</td>
<td rowspan="2">61.6</td>
<td rowspan="2">48.8</td>
<td rowspan="2">NS</td>
<td rowspan="2">−21</td></tr>
<tr>
<td> medication costs, <italic>%</italic> (<xref ref-type="table-fn" rid="table-fn2-1741826711410835">*</xref>n = 682)</td></tr>
<tr>
<td> Dyslipidemic, %</td>
<td colspan="5">91.6</td></tr>
<tr>
<td> Lipid-lowering treatment, %</td>
<td>9.4</td>
<td>10.5</td>
<td>21.6</td>
<td>NS</td>
<td>+105</td></tr>
<tr>
<td> Total alcohol intake, g/week (<xref ref-type="table-fn" rid="table-fn2-1741826711410835">*</xref>n = 717)</td>
<td>64.2(126.6)</td>
<td colspan="4"/></tr>
<tr>
<td> Duration of hypertension, y (<xref ref-type="table-fn" rid="table-fn2-1741826711410835">*</xref>n = 643)<xref ref-type="table-fn" rid="table-fn3-1741826711410835">#</xref></td>
<td>11.8(10.5)</td>
<td colspan="4"/></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711410835"><p>H2000, the data of the Health 2000 Survey; Sll, database of the Social Insurance Institution; ASA, acetylsalicylic acid; NS, non-significant. Data expressed as mean (SD) or percentages.</p></fn>
<fn id="table-fn2-1741826711410835"><label>*</label><p>Number of observations in the data of the Health 2000 Survey, in case of missing values.</p></fn>
<fn id="table-fn3-1741826711410835"><label>#</label><p>Duration of hypertension, confirmed by a physician at the health examination and determined only among those classified as hypertensives.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table2-1741826711410835" position="float"><label>Table 2.</label><caption><p>Utilization of blood pressure lowering drugs among Finnish adult uncomplicated hypertensives receiving antihypertensive medication according to the Health 2000 Survey and the database of Social Insurance Institution</p></caption>
<graphic alternate-form-of="table2-1741826711410835" xlink:href="10.1177_1741826711410835-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="4"/><th>2000–2001</th>
<th>2000</th>
<th rowspan="4"><italic>P</italic></th></tr>
<tr><th>H2000</th>
<th>Sll</th></tr>
<tr><th>Hypertensives</th>
<th>Hypertensives</th></tr>
<tr><th>(n = 729)</th>
<th>(n = 428 986)</th></tr></thead>
<tbody align="left">
<tr>
<td>β-blocker(s)</td>
<td>49.7</td>
<td>51.6</td>
<td>NS</td></tr>
<tr>
<td>Diuretic(s)</td>
<td>35.1</td>
<td>39.2</td>
<td>0.04</td></tr>
<tr>
<td>CCB(s)</td>
<td>26.5</td>
<td>26.9</td>
<td>NS</td></tr>
<tr>
<td>ACE inhibitor(s)</td>
<td>28.8</td>
<td>27.8</td>
<td>NS</td></tr>
<tr>
<td>ARB(s)</td>
<td>8.3</td>
<td>9.3</td>
<td>NS</td></tr>
<tr>
<td>RAS blocker(s)</td>
<td>37.2</td>
<td>36.8</td>
<td>NS</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1741826711410835"><p>H2000, the data of the Health 2000 Survey; Sll, database of the Social Insurance Institution; β-blocker, beta-blocker; CCB, calcium channel blocker; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; RAS, renin-angiotensin-system; NS, non-significant. Data expressed as percentages. Patients may have more than 1 antihypertensive medication or may have been taking a combination drug product, therefore the percentages do not add to 100%. If a combination drug product was taken, the drug was counted in both drug classes.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec14-1741826711410835"><title>Treatment of hypertension and dyslipidaemia between 2000 and 2006 (SII database)</title>
<p>Utilization of BP-lowering and lipid-lowering drugs for 428,986 uncomplicated hypertensives in 2000 and 591,206 uncomplicated hypertensives in 2006 are described in detail (subgroups also included) in <xref ref-type="table" rid="table3-1741826711410835">Table 3</xref>. In addition, relative changes in the drug use between 2000 and 2006 are assessed for each drug. Moreover, all assessments are done for all hypertensives, and separately for those with moderate to severe hypertension and mild hypertension.
<table-wrap id="table3-1741826711410835" position="float"><label>Table 3.</label><caption><p>Utilization of blood pressure and lipid lowering drugs among Finnish adult uncomplicated hypertensives receiving antihypertensive medication in 2000 and 2006 according to the database of Social Insurance Institution</p></caption>
<graphic alternate-form-of="table3-1741826711410835" xlink:href="10.1177_1741826711410835-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="3"/><th colspan="3">All hypertensives<sup><xref ref-type="table-fn" rid="table-fn6-1741826711410835">†</xref></sup><hr/></th>
<th colspan="3">Moderately to severely hypertensives<hr/></th>
<th colspan="3">Mildly hypertensives<hr/></th></tr>
<tr><th>2000</th>
<th>2006</th>
<th><italic>Relative</italic></th>
<th>2000</th>
<th>2006</th>
<th><italic>Relative</italic></th>
<th>2000</th>
<th>2006</th>
<th><italic>Relative</italic></th></tr>
<tr><th>(n = 428 986)</th>
<th>(n = 591 206)</th>
<th><italic>Change</italic></th>
<th>(n = 264 313)</th>
<th>(n = 288 352)</th>
<th><italic>Change</italic></th>
<th>(n = 164 673)</th>
<th>(n = 302 854)</th>
<th><italic>Change</italic></th></tr></thead>
<tbody align="left">
<tr>
<td>Mean number of antihypertensive drugs</td>
<td>1.75(0.88)</td>
<td>1.82(0.92)</td>
<td>+4</td>
<td>1.95(0.94)</td>
<td>2.14(0.98)</td>
<td>+10</td>
<td>1.42(0.67)</td>
<td>1.51(0.73)</td>
<td>+6</td></tr>
<tr>
<td>β-blocker(s)</td>
<td>51.6</td>
<td>48.0</td>
<td>−7</td>
<td>50.1</td>
<td>48.4</td>
<td>−3</td>
<td>54.1</td>
<td>47.7</td>
<td>−12</td></tr>
<tr>
<td> β1<italic>-selective blocker(s)</italic></td>
<td>39.6</td>
<td>40.7</td>
<td>+3</td>
<td>41.0</td>
<td>42.9</td>
<td>+5</td>
<td>37.4</td>
<td>38.6</td>
<td>+3</td></tr>
<tr>
<td><italic> Non-selective <italic>β</italic>-blocker(s)</italic></td>
<td>8.5</td>
<td>5.1</td>
<td>−40</td>
<td>4.9</td>
<td>2.2</td>
<td>−54</td>
<td>14.3</td>
<td>7.8</td>
<td>−46</td></tr>
<tr>
<td><italic> Alfa- and <italic>β</italic>-andrenergic antagonist(s)</italic></td>
<td>3.8</td>
<td>2.5</td>
<td>−33</td>
<td>4.5</td>
<td>3.6</td>
<td>−20</td>
<td>2.7</td>
<td>1.6</td>
<td>−43</td></tr>
<tr>
<td>Diuretic(s)</td>
<td>39.2</td>
<td>42.0</td>
<td>+7</td>
<td>44.4</td>
<td>51.0</td>
<td>+15</td>
<td>30.8</td>
<td>33.5</td>
<td>+9</td></tr>
<tr>
<td><italic> Thiazide diuretic(s)</italic></td>
<td>32.0</td>
<td>35.2</td>
<td>+10</td>
<td>38.4</td>
<td>44.7</td>
<td>+16</td>
<td>21.8</td>
<td>26.2</td>
<td>+20</td></tr>
<tr>
<td><italic> Potassium-sparing diuretic(s)</italic></td>
<td>18.4</td>
<td>11.3</td>
<td>−39</td>
<td>19.3</td>
<td>12.0</td>
<td>−38</td>
<td>17.0</td>
<td>10.6</td>
<td>−37</td></tr>
<tr>
<td><italic> Loop diuretic(s)</italic></td>
<td>6.8</td>
<td>6.6</td>
<td>−3</td>
<td>5.7</td>
<td>6.3</td>
<td>+10</td>
<td>8.7</td>
<td>7.0</td>
<td>−20</td></tr>
<tr>
<td><italic> Aldosteron antagonist(s)</italic></td>
<td>1.1</td>
<td>1.3</td>
<td>+17</td>
<td>1.1</td>
<td>1.4</td>
<td>+32</td>
<td>1.1</td>
<td>1.1</td>
<td>+2</td></tr>
<tr>
<td>ARB(S)</td>
<td>9.3</td>
<td>27.9</td>
<td>+201</td>
<td>10.2</td>
<td>32.6</td>
<td>+221</td>
<td>7.8</td>
<td>23.4</td>
<td>+199</td></tr>
<tr>
<td>CCB(S)</td>
<td>26.9</td>
<td>26.0</td>
<td>−3</td>
<td>34.3</td>
<td>37.2</td>
<td>+8</td>
<td>15.0</td>
<td>15.3</td>
<td>+2</td></tr>
<tr>
<td><italic> Dihydropyridine(s)</italic></td>
<td>21.1</td>
<td>23.7</td>
<td>+12</td>
<td>27.0</td>
<td>34.0</td>
<td>+26</td>
<td>11.6</td>
<td>13.9</td>
<td>+20</td></tr>
<tr>
<td><italic> Diltiazem(s)</italic></td>
<td>4.6</td>
<td>1.7</td>
<td>−64</td>
<td>6.5</td>
<td>2.8</td>
<td>−56</td>
<td>1.6</td>
<td>0.6</td>
<td>−65</td></tr>
<tr>
<td><italic> Verapamil(s)</italic></td>
<td>1.3</td>
<td>0.6</td>
<td>−50</td>
<td>0.9</td>
<td>0.5</td>
<td>−52</td>
<td>1.8</td>
<td>0.8</td>
<td>−57</td></tr>
<tr>
<td>ACE inhibitor(s)</td>
<td>27.8</td>
<td>25.0</td>
<td>−10</td>
<td>35.1</td>
<td>30.2</td>
<td>−14</td>
<td>16.1</td>
<td>20.0</td>
<td>+24</td></tr>
<tr>
<td>RAS blocker(s)</td>
<td>36.8</td>
<td>52.5</td>
<td>+42</td>
<td>45.0</td>
<td>62.3</td>
<td>+39</td>
<td>23.8</td>
<td>43.1</td>
<td>+81</td></tr>
<tr>
<td>Lipid-lowering drug(s)</td>
<td>10.5</td>
<td>21.6</td>
<td>+105</td>
<td>11.7</td>
<td>24.7</td>
<td>+111</td>
<td>8.6</td>
<td>18.6</td>
<td>+115</td></tr>
<tr>
<td> Statin(s)</td>
<td>10.3</td>
<td>21.3</td>
<td>+108</td>
<td>11.4</td>
<td>24.4</td>
<td>+114</td>
<td>8.5</td>
<td>18.4</td>
<td>+117</td></tr>
<tr>
<td> Fibrate(s)</td>
<td>0.29</td>
<td>0.11</td>
<td>−62</td>
<td>0.35</td>
<td>0.13</td>
<td>−63</td>
<td>0.18</td>
<td>0.10</td>
<td>−44</td></tr>
<tr>
<td>Other lipid lowering drug(s)</td>
<td>0.06</td>
<td>0.48</td>
<td>+700</td>
<td>0.06</td>
<td>0.52</td>
<td>+767</td>
<td>0.07</td>
<td>0.45</td>
<td>+543</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1741826711410835"><p>β-blocker, beta-blocker; CCB, calcium channel blocker; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; RAS blocker, renin-angiotensin-system blocker. Data expressed as mean (SD) or percentages.</p></fn>
<fn id="table-fn6-1741826711410835"><label>†</label><p>Includes both moderately to severely hypertensives and mildly hypertensives. Moderately to severely hypertensive patients are entitled to reimbursement for hypertension medication costs conceded by the Social Insurance Institution during the observed year. A patients may have taken several drugs or may have been taking a combination drug product, therefore percentages do not ad to 100%. If a combination drug product was taken, the drug was counted in both drug classes.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>In <xref ref-type="table" rid="table4-1741826711410835">Table 4</xref>, for the same uncomplicated hypertensive patients as those in <xref ref-type="table" rid="table3-1741826711410835">Table 3</xref>, utilization of BP-lowering drugs and relative changes between 2000 and 2006 are described in detail for monotherapy as well as two-drug combinations and combinations of at least three different antihypertensive drugs.
<table-wrap id="table4-1741826711410835" position="float"><label>Table 4.</label><caption><p>Utilization of blood pressure lowering drugs among Finnish adult uncomplicated hypertensives receiving antihypertensive medication in 2000 and 2006 according to the database of Social Insurance Institution</p></caption>
<graphic alternate-form-of="table4-1741826711410835" xlink:href="10.1177_1741826711410835-table4a.tif"/>
<graphic alternate-form-of="table4-1741826711410835" xlink:href="10.1177_1741826711410835-table4b.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="3"/><th colspan="3">All hypertensives<sup><xref ref-type="table-fn" rid="table-fn8-1741826711410835">†</xref></sup><hr/></th>
<th colspan="3">Moderately to severely hypertensives<hr/></th>
<th colspan="3">Mildly hypertensives<hr/></th></tr>
<tr><th>2000</th>
<th>2006</th>
<th><italic>Relative</italic></th>
<th>2000</th>
<th>2006</th>
<th><italic>Relative</italic></th>
<th>2000</th>
<th>2006</th>
<th><italic>Relative</italic></th></tr>
<tr><th>(n = 428 986)</th>
<th>(n = 591 206)</th>
<th><italic>Change</italic></th>
<th>(n = 264 313)</th>
<th>(n = 288 352)</th>
<th><italic>Change</italic></th>
<th>(n = 164 673)</th>
<th>(n = 302 854)</th>
<th><italic>Change</italic></th></tr></thead>
<tbody align="left">
<tr>
<td>monotherapy</td>
<td>49.6</td>
<td>45.8</td>
<td>−8</td>
<td>38.8</td>
<td>29.9</td>
<td>−23</td>
<td>67.0</td>
<td>61.0</td>
<td>−9</td></tr>
<tr>
<td> β-blocker</td>
<td>24.4 (49.1)</td>
<td>19.5 (42.5)</td>
<td>−20</td>
<td>14.4 (37.1)</td>
<td>8.8 (29.5)</td>
<td>−39</td>
<td>40.4 (60.4)</td>
<td>29.6 (48.5)</td>
<td>−27</td></tr>
<tr>
<td> ARB</td>
<td>3.2 (6.5)</td>
<td>8.5 (18.6)</td>
<td>+165</td>
<td>2.6 (6.7)</td>
<td>6.2 (20.8)</td>
<td>+138</td>
<td>4.2 (6.2)</td>
<td>10.7 (17.6)</td>
<td>+157</td></tr>
<tr>
<td> ACE inhibitors</td>
<td>9.7 (19.6)</td>
<td>8.4 (18.2)</td>
<td>−14</td>
<td>10.2 (26.4)</td>
<td>6.8 (22.6)</td>
<td>−34</td>
<td>8.9 (13.2)</td>
<td>9.9 (16.2)</td>
<td>+12</td></tr>
<tr>
<td> CCB</td>
<td>9.6 (19.4)</td>
<td>6.9 (14.9)</td>
<td>−29</td>
<td>10.1 (26.0)</td>
<td>6.9 (23.1)</td>
<td>−32</td>
<td>8.9 (13.3)</td>
<td>6.8 (11.2)</td>
<td>−23</td></tr>
<tr>
<td> Diuretic</td>
<td>2.4 (4.9)</td>
<td>2.5 (5.5)</td>
<td>+3</td>
<td>1.3 (3.3)</td>
<td>1.1 (3.6)</td>
<td>−18</td>
<td>4.3 (6.4)</td>
<td>3.9 (6.4)</td>
<td>−9</td></tr>
<tr>
<td> Other</td>
<td>0.26 (0.52)</td>
<td>0.13 (0.28)</td>
<td>−50</td>
<td>0.2 (0.51)</td>
<td>0.10 (0.34)</td>
<td>−50</td>
<td>0.35 (0.52)</td>
<td>0.16 (0.26)</td>
<td>−54</td></tr>
<tr>
<td>2 drugs</td>
<td>30.6</td>
<td>32.5</td>
<td>+6</td>
<td>33.8</td>
<td>36.9</td>
<td>+9</td>
<td>25.3</td>
<td>28.4</td>
<td>+12</td></tr>
<tr>
<td> Diuretic and ARB</td>
<td>1.8 (6.0)</td>
<td>7.1 (21.8)</td>
<td>+288</td>
<td>2.0 (5.9)</td>
<td>8.1 (21.9)</td>
<td>+309</td>
<td>1.6 (6.3)</td>
<td>6.2 (21.7)</td>
<td>+290</td></tr>
<tr>
<td> β-blocker and CCB</td>
<td>6.3 (20.5)</td>
<td>4.9 (15.2)</td>
<td>−21</td>
<td>8.4 (24.7)</td>
<td>7.3 (19.7)</td>
<td>−13</td>
<td>2.9 (11.4)</td>
<td>2.7 (9.6)</td>
<td>−6</td></tr>
<tr>
<td> Diuretic and ACE inhibitor</td>
<td>5.9 (19.4)</td>
<td>4.7 (14.4)</td>
<td>−21</td>
<td>7.7 (22.7)</td>
<td>6.0 (16.2)</td>
<td>−22</td>
<td>3.1 (12.3)</td>
<td>3.5 (12.3)</td>
<td>+12</td></tr>
<tr>
<td> β-blocker and Diuretic</td>
<td>3.0 (9.9)</td>
<td>3.6 (11.0)</td>
<td>+18</td>
<td>3.1 (9.2)</td>
<td>3.3 (8.9)</td>
<td>+6</td>
<td>2.9 (11.6)</td>
<td>3.8 (13.5)</td>
<td>+31</td></tr>
<tr>
<td> β-blocker and ACE inhibitor</td>
<td>2.7 (8.7)</td>
<td>2.5 (7.7)</td>
<td>−6</td>
<td>3.5 (10.3)</td>
<td>2.9 (7.8)</td>
<td>−18</td>
<td>1.3 (5.3)</td>
<td>2.1 (7.5)</td>
<td>+60</td></tr>
<tr>
<td> β-blocker and ARB</td>
<td>0.8 (2.6)</td>
<td>2.1 (6.3)</td>
<td>+158</td>
<td>0.96 (2.8)</td>
<td>2.4 (6.6)</td>
<td>+154</td>
<td>0.55 (2.2)</td>
<td>1.7 (6.0)</td>
<td>+209</td></tr>
<tr>
<td> CCB and ACE inhibitor</td>
<td>1.6 (5.1)</td>
<td>1.6 (4.9)</td>
<td>+3</td>
<td>2.2 (6.4)</td>
<td>2.3 (6.3)</td>
<td>+7</td>
<td>0.53 (2.1)</td>
<td>0.88 (3.1)</td>
<td>+66</td></tr>
<tr>
<td> CCB and ARB</td>
<td>0.47 (1.5)</td>
<td>1.3 (3.8)</td>
<td>+166</td>
<td>0.63 (1.9)</td>
<td>1.8 (5.0)</td>
<td>+190</td>
<td>0.21 (0.83)</td>
<td>0.7 (2.5)</td>
<td>+233</td></tr>
<tr>
<td> Diuretic and CCB</td>
<td>0.64 (2.1)</td>
<td>0.52 (1.6)</td>
<td>−19</td>
<td>0.85 (2.5)</td>
<td>0.68 (1.8)</td>
<td>−20</td>
<td>0.31 (1.2)</td>
<td>0.37 (1.3)</td>
<td>+19</td></tr>
<tr>
<td> ACE inhibitor and ARB</td>
<td>0.06 (0.2)</td>
<td>0.10 (0.31)</td>
<td>+67</td>
<td>0.05 (0.15)</td>
<td>0.07 (0.19)</td>
<td>+40</td>
<td>0.07 (0.28)</td>
<td>0.13 (0.46)</td>
<td>+86</td></tr>
<tr>
<td> Other 2 drug combination<sup><xref ref-type="table-fn" rid="table-fn9-1741826711410835">‡</xref></sup></td>
<td>7.3 (24)</td>
<td>4.2 (13.0)</td>
<td>−42</td>
<td>4.6 (13.5)</td>
<td>2.1 (5.7)</td>
<td>−54</td>
<td>11.8 (46.5)</td>
<td>6.3 (22.1)</td>
<td>−47</td></tr>
<tr>
<td>≥3 drugs</td>
<td>19.8</td>
<td>21.6</td>
<td>+9</td>
<td>27.3</td>
<td>33.2</td>
<td>+22</td>
<td>7.8</td>
<td>10.6</td>
<td>+37</td></tr>
<tr>
<td> Diuretic(s) and B-blocker(s) and ARB(s)</td>
<td>1.5 (7.6)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>5.0 (22.9)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+228</td>
<td>2.1 (7.7)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>7.9 (23.8)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+278</td>
<td>0.57 (7.4)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>2.1 (20.2)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+275</td></tr>
<tr>
<td> Diuretic(s) and B-blocker(s) and CCB(s)</td>
<td>3.3 (16.8)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>4.4 (20.5)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+33</td>
<td>5.0 (18.2)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>7.8 (23.4)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+56</td>
<td>0.68 (8.8)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>1.2 (117)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+82</td></tr>
<tr>
<td> Diuretic(s) and β-blocker(s) and ACE mhibitor(s)</td>
<td>4.2 (21.4)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>4.3 (19.6)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+0.5</td>
<td>6.2 (22.7)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>6.8 (20.3)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+9</td>
<td>1.1 (14.1)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>1.9 (17.5)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+71</td></tr>
<tr>
<td> Diuretic(s) and CCB(s) and ARB(s)</td>
<td>0.96 (4.8)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>3.7 (17.2)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+289</td>
<td>1.4 (5.1)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>6.3 (19.0)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+351</td>
<td>0.27 (3.5)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>1.3 (11 9)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+367</td></tr>
<tr>
<td> Diuretic(s) and CCB(s) and ACE inhibitor(s)</td>
<td>2.6 (12.9)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>2.8 (13.1)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+ 11</td>
<td>3.9 (14.2)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>5.0 (15.0)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+28</td>
<td>0.41 (5.3)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.79 (7.5)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+93</td></tr>
<tr>
<td> β-blocker(s) and CCB(s) and ARB(s)</td>
<td>0.7 (3.6)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>2.3 (10.5)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+221</td>
<td>1.1 (3.8)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>4.0 (12.2)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+285</td>
<td>0.16 (2.1)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.6 (5.7)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+275</td></tr>
<tr>
<td> β-blocker(s) and CCB(s) and ACE(s)</td>
<td>1.7 (8.9)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>2.1 (9.7)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+ 19</td>
<td>2.7 (9.8)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>3.7 (11.2)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+38</td>
<td>0.27 (3.5)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.56 (5.3)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+ 107</td></tr>
<tr>
<td> Diuretic(s) and ACE inhibitor(s) and ARB(s)</td>
<td>0.13 (0.7)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.24 (1.1)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+85</td>
<td>0.16 (0.6)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.34 (1.0)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+ 113</td>
<td>0.07 (0.9)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.15 (1.4)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+ 114</td></tr>
<tr>
<td> β-blocker(s) and ACE(s) and ARB(s)</td>
<td>0.07 (0.4)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.16 (0.7)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+ 129</td>
<td>0.1 (0.4)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.23 (0.7)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+ 130</td>
<td>0.04 (0.52)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.08 (0.75)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+ 100</td></tr>
<tr>
<td> CCB(s) and ACE inhibitor(s) and ARB(s)</td>
<td>0.06 (0.3)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.11 (0.5)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+83</td>
<td>0.08 (0 3)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.17 (0.5)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+ 113</td>
<td>0.02 (0.26)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>0.04 (0.38)<xref ref-type="table-fn" rid="table-fn10-1741826711410835">*</xref></td>
<td>+ 100</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1741826711410835"><p>β-blocker, beta-blocker; CCB, calcium channel blocker; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; RAS blocker, renin-angiotensin-system blocker. Data expressed as Percentage. Percentages in parenthesis are calculated from monotheraphy. 2-drug combinations, and ≥3-drug combinations, respectively.</p></fn>
<fn id="table-fn8-1741826711410835"><label>†</label><p>Includes both moderately to severely hypertensives and mildly hypertensives. Moderately to severaly hypertensive patients are entitied to reimbursement for hypertension medication costs conceded by the Social Insurance Institution during the observed year. If a combination drug product was taken the drug was counted in both drug classes.</p></fn>
<fn id="table-fn9-1741826711410835"><label>‡</label><p>Mostly involved 2 different diuretics (for example one thiazide diuretic and one potassium-sparing diuretic).</p></fn>
<fn id="table-fn10-1741826711410835"><label>*</label><p>Patients may take more than 3 antihypertensive drugs or may have been taking acombination drug product, therefore the percentages do not add to 100%.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec15-1741826711410835"><title>Estimated control of hypertension and reduction of cardiovascular morbidity</title>
<p>According to H2000, in 2000, 30.3% of the treated adult uncomplicated hypertensives had a BP &lt;140/90 mmHg. Accounting for the changes in age, sex, and mean number of BP-lowering drugs and comparing 2006 with 2000 indicates that the BP of an estimated 33.9% of the treated Finnish adult uncomplicated hypertensives has been retained &lt;140/90 mmHg in 2006. The observed change in the treatment would reduce strokes by approximately 3% and IHD events by 2%.</p>
<p>By adding one ordinary BP-lowering drug with a half standard dose for those with a systolic BP of 140 mmHg or more or a diastolic BP of 90 mmHg or more would improve the control of hypertension from 33.9% to 47.8%, and even up to 67.3% if one to two BP-lowering drugs with half standard doses had been added on the therapy (<xref ref-type="fig" rid="fig2-1741826711410835">Figure 2</xref>).
<fig id="fig2-1741826711410835" position="float"><label>Figure 2.</label><caption><p>Impact on blood pressure (BP) control after intensifying treatment, when needed, with one to two half standard/standard doses of ordinary antihypertensive regimen in 2006. Distribution of primary BP is shown with full lines. Theoretical distribution of BP after intensification of treatment with one half standard dose, one standard dose, one to two half standard doses, and one to two standard doses, when needed, is shown with dashed lines. No drugs were added if a BP was already below 140/90 mmHg. The second drug was added only if the control target of hypertension (BP&lt;140/90 mmHg) was not achieved with the first drug add-on therapy. Percentages on the left side of the arrow shows control of BP before intensification the drug therapy; percentages on the right side of the arrow shows data thereafter.</p></caption><graphic xlink:href="10.1177_1741826711410835-fig2.tif"/></fig></p>
<p>This intensified treatment would reduce strokes by 18% and 28% and IHD events by 13% and 21%, with a one and one to two half standard doses add-on therapy.</p>
</sec>
</sec>
<sec id="sec16-1741826711410835" sec-type="discussion"><title>Discussion</title>
<p>Between 2000 and 2006, the number of treated adult uncomplicated hypertensives increased from nearly 430,000 to more than 590,000, while the mean number of antihypertensive drugs increased from 1.7 to 1.8. At the same time the prescribing pattern for monotherapy regimen decreased while combination antihypertensive medication increased. The proportion of mildly hypertensives nearly doubled while moderately to severely hypertensives increased only slightly. The increase in the number and proportion of subjects treated for milder forms of hypertension suggest that clinicians have complied with national and international guidelines in that respect.<sup><xref ref-type="bibr" rid="bibr7-1741826711410835">7</xref></sup></p>
<p>We observed also notable changes in the preference of drugs in both monotherapy and in combination therapy. The use of RAS blockers advantageously increased &gt;40%. Use of ARBs more than doubled in monotherapy and increased two-fold to three-fold in combination therapy. Thereby, ARBs became thirdly popular drugs after beta-blockers and diuretics while ACE inhibitors dropped from third to fifth place after CCBs. Use of beta-blockers decreased, although they still remained most frequently used drugs among uncomplicated hypertensive patients with no specific indications for their use. Utilization of diuretics, especially thiazide diuretics, increased due to their frequent use in combination therapy with ARBs. On the contrary, at the same time, utilization of ACE inhibitors, and CCBs, relatively decreased. It seems clear that quite often ACE inhibitors have been replaced by increasingly marketed ARBs, which are better tolerated.</p>
<p>By the end of 2006, the two-drug combination most frequently used was an ARB combined with a diuretic, which is in line with findings from RCT trials<sup><xref ref-type="bibr" rid="bibr17-1741826711410835">17</xref></sup> and guidelines.<sup><xref ref-type="bibr" rid="bibr7-1741826711410835">7</xref></sup> The combination of at least three drugs most often prescribed became a combination of diuretics, beta-blockers, and ARBs. According to the guidelines, the most rational three-drug combination appears to be a blocker of renin−angiotensin system (RAS), a CCB, and a diuretic.<sup><xref ref-type="bibr" rid="bibr7-1741826711410835">7</xref></sup></p>
<p>According to our study, it seems that, as first-line agents, beta-blockers (especially among mildly hypertensives) were chosen more frequently than diuretics, CCBs, ACE inhibitors, or ARBs. It is, however, worth noting that the status of beta-blockers as first-line agents has been impugned. British Hypertension Society Guidelines for hypertension management, for instance, placed beta-blockers within brackets in the AB/CD algorithm in 2004.<sup><xref ref-type="bibr" rid="bibr18-1741826711410835">18</xref></sup> However, since then, recently published hypertension guidelines<sup><xref ref-type="bibr" rid="bibr7-1741826711410835">7</xref></sup> have reappraised a number of trials in favour of<sup><xref ref-type="bibr" rid="bibr19-1741826711410835">19</xref>,<xref ref-type="bibr" rid="bibr20-1741826711410835">20</xref></sup> and against<sup><xref ref-type="bibr" rid="bibr21-1741826711410835">21</xref></sup><sup>−</sup><sup><xref ref-type="bibr" rid="bibr23-1741826711410835">23</xref></sup> beta-blockers but eventually stated that the treatments of hypertension can be initiated with beta-blockers, even in monotherapy. Still, recent guidelines have acknowledged and there is evidence that beta-blockers decrease the risk of stroke less than other antihypertensive agents, especially among elderly patients.<sup><xref ref-type="bibr" rid="bibr24-1741826711410835">24</xref></sup> Accordingly, beta-blockers and especially combination of beta-blockers and diuretics should be avoided as primary treatment among individuals with a metabolic syndrome or increased risk for new-onset diabetes.<sup><xref ref-type="bibr" rid="bibr25-1741826711410835">25</xref></sup><sup>−</sup><sup><xref ref-type="bibr" rid="bibr27-1741826711410835">27</xref></sup> Likeways, nonvasodilating beta-blockers and diuretics have negative effects on erectile functions.<sup><xref ref-type="bibr" rid="bibr28-1741826711410835">28</xref></sup> Erectile dysfunction is a prevalent condition in hypertensive males and may predict cardiovascular events in the future.<sup><xref ref-type="bibr" rid="bibr7-1741826711410835">7</xref></sup> In our study, fortunately, for two-drug combinations, the combination of a beta-blocker and a diuretic retreated from third to fourth place during the follow-up time.</p>
<p>A combination therapy is usually required to achieve a proper control of BP.<sup><xref ref-type="bibr" rid="bibr7-1741826711410835">7</xref></sup> A low-dose combination therapy increases the efficacy and reduces adverse effects of the treatment.<sup><xref ref-type="bibr" rid="bibr6-1741826711410835">6</xref>,<xref ref-type="bibr" rid="bibr8-1741826711410835">8</xref></sup> In a period of 6 years we observed an increase of only 0.15 in the mean number of antihypertensive drugs per treated subject. According to Law’s meta-analyses,<sup><xref ref-type="bibr" rid="bibr6-1741826711410835">6</xref></sup> this can be expected to reduce systolic BP by 1.08−1.38 mmHg and diastolic BP by 0.67−0.84 mmHg with half standard and standard doses, respectively. The expected decrease in BP would reduce strokes by only 3.8–4.8%, and IHD events by only 3.4–4.2%. However, an addition of one or two half standard doses when needed for subjects with a BP at least 140/90 mmHg would improve control of hypertension from one-third up to two-thirds and reduce the incidence of strokes by 28% and IHD events by 21%. Therefore, an addition to the number of antihypertensive drugs is clearly needed in the future, to improve control of hypertension and to decrease cardiovascular morbidity among uncomplicated hypertensive patients.</p>
<p>Hypertensive patients will also benefit from lipid-lowering drugs.<sup><xref ref-type="bibr" rid="bibr29-1741826711410835">29</xref></sup> According to our study, utilization of lipid-lowering drugs seems to be unsatisfactory among uncomplicated hypertensive patients although the proportion of subjects treated with statins more than doubled in 6 years, to a level of 21.6%. The utilization of fibrates and other lipid-lowering drugs remained very low.</p>
<p>The database of the SII included practically 100% of the prescriptions on antihypertensive and lipid-lowering drugs purchased by the Finnish population during late 2000 and late 2006. The drug utilization data from the SII database proved to be largely in line with the data observed from the population-based H2000 survey, and vice versa. Therefore, the results presented in this paper can be considered comparatively accurate and reliable. To date, however, this is the first longitudinal study prescribing in detail the use of different antihypertensive drug combinations (including three or more antihypertensive drugs) among adult-treated uncomplicated hypertensive patients at a population-based level. Earlier published studies concerning treated uncomplicated hypertensives have either involved a relatively small number of patients or have been made in special clinics or have included hypertensives only of a certain stage, and are therefore not comparable wih our study.</p>
<p>There are some limitations in our study. Firstly, BP was measured only in the population-based H2000 survey in 2000 and 2001. Secondly, BP was determined as a mean of two measurements made at a single occasion, which may lead to an overestimation of hypertension and an underestimation of the control of hypertension. Thirdly, despite of careful exclusions of patients with diabetes, CHD, cardiac arrhythmias, and CHF, our study may still include some unidentifiable subjects using BP-lowering drugs not only for the treatment of hypertension but also for the treatment of other diseases such as migraine and essential tremor. However, we estimate that the proportion of these subjects is extremely low (1–2% of the studied populations) and would therefore not influence our findings.</p>
<p>In summary, utilization of evidence-based drug therapies among uncomplicated hypertensive patients has increased between 2000 and 2006, predicting slight benefits in cardiovascular morbidity and mortality. There seems to be an unceasing relative overuse of beta-blockers among uncomplicated hypertensive patients. In spite of positive changes in the utilization of antihypertensive drugs, underutilization of combination therapy and irrational drug combinations remain a matter of concern. The reasons for this must be patient-related, physician-related and medical environment/healthcare system-related. Yet, the reasons are complex; we believe that clinical inertia is one of the major factors behind the lag. However, as calculated in this study, intensifying treatment of uncomplicated hypertensives by one half standard dose of BP-lowering regimen, when needed, would increase the control of hypertension from 34% to 48%, reduce strokes by 18%, and reduce ischaemic heart disease events by 13%.</p>
</sec>
</body>
<back>
<ack><title>Acknowledgments</title>
<p>We extend our thanks to the Social Insurance Institution of Finland, the field staff and support organizations of the Health 2000 Survey, and the Finnish National Institute for Health and Welfare.</p>
</ack>
<sec id="sec17-1741826711410835"><title>Funding</title>
<p>Jyväskylä Central Hospital, Turku University Hospital, Turku University Foundation, the Finnish Foundation for Cardiovascular Research, and the Kauhajoki Cultural Foundation are gratefully acknowledged for their financial support.</p>
</sec>
<sec id="sec18-1741826711410835"><title>Conflict of interest</title>
<p>None.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826711410835"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Hebert</surname><given-names>P</given-names></name><name><surname>Fiebach</surname><given-names>NH</given-names></name><name><surname>Eberlein</surname><given-names>KA</given-names></name><etal/></person-group>. <article-title>Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context</article-title>. <source>Lancet</source> <year>1990</year>; <volume>335</volume>(<issue>8693</issue>): <fpage>827</fpage>–<lpage>838</lpage>.</citation></ref>
<ref id="bibr2-1741826711410835"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>MR</given-names></name><name><surname>Morris</surname><given-names>JK</given-names></name><name><surname>Wald</surname><given-names>NJ</given-names></name></person-group>. <article-title>Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies</article-title>. <source>BMJ</source> <year>2009</year>; <volume>338</volume>(<issue>7705</issue>): <fpage>b1665</fpage>–<lpage>b1665</lpage>.</citation></ref>
<ref id="bibr3-1741826711410835"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawes</surname><given-names>CM</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Parag</surname><given-names>V</given-names></name><name><surname>Suh</surname><given-names>I</given-names></name><name><surname>Ueshima</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Blood pressure and cardiovascular disease in the Asia Pacific region</article-title>. <source>J Hypertens</source> <year>2003</year>; <volume>21</volume>(<issue>4</issue>): <fpage>707</fpage>–<lpage>716</lpage>.</citation></ref>
<ref id="bibr4-1741826711410835"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawes</surname><given-names>CM</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Feigin</surname><given-names>VL</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name></person-group>. <article-title>Blood pressure and stroke: an overview of published reviews</article-title>. <source>Stroke</source> <year>2004</year>; <volume>35</volume>(<issue>4</issue>): <fpage>1024</fpage>–<lpage>1024</lpage>.</citation></ref>
<ref id="bibr5-1741826711410835"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Lacy</surname><given-names>PS</given-names></name><name><surname>Thom</surname><given-names>SM</given-names></name><name><surname>Cruickshank</surname><given-names>K</given-names></name><name><surname>Stanton</surname><given-names>A</given-names></name><name><surname>Collier</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study</article-title>. <source>Circulation</source> <year>2006</year>; <volume>113</volume>(<issue>9</issue>): <fpage>1213</fpage>–<lpage>1225</lpage>.</citation></ref>
<ref id="bibr6-1741826711410835"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>MR</given-names></name><name><surname>Wald</surname><given-names>NJ</given-names></name><name><surname>Morris</surname><given-names>JK</given-names></name><name><surname>Jordan</surname><given-names>RE</given-names></name></person-group>. <article-title>Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials</article-title>. <source>BMJ</source> <year>2003</year>; <volume>326</volume>(<issue>7404</issue>): <fpage>1427</fpage>–<lpage>1427</lpage>.</citation></ref>
<ref id="bibr7-1741826711410835"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Laurent</surname><given-names>S</given-names></name><name><surname>Agabiti-Rosei</surname><given-names>E</given-names></name><name><surname>Ambrosioni</surname><given-names>E</given-names></name><name><surname>Burnier</surname><given-names>M</given-names></name><name><surname>Caulfield</surname><given-names>MJ</given-names></name><etal/></person-group>. <article-title>Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document</article-title>. <source>J Hypertens</source> <year>2009</year>; <volume>27</volume>(<issue>11</issue>): <fpage>2121</fpage>–<lpage>2158</lpage>.</citation></ref>
<ref id="bibr8-1741826711410835"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wald</surname><given-names>DS</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Morris</surname><given-names>JK</given-names></name><name><surname>Bestwick</surname><given-names>JP</given-names></name><name><surname>Wald</surname><given-names>NJ</given-names></name></person-group>. <article-title>Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials</article-title>. <source>Am J Med</source> <year>2009</year>; <volume>122</volume>(<issue>3</issue>): <fpage>290</fpage>–<lpage>300</lpage>.</citation></ref>
<ref id="bibr9-1741826711410835"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name></person-group>. <article-title>Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage</article-title>. <source>J Hypertens</source> <year>2008</year>; <volume>26</volume>(<issue>2</issue>): <fpage>164</fpage>–<lpage>168</lpage>.</citation></ref>
<ref id="bibr10-1741826711410835"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kastarinen</surname><given-names>M</given-names></name><name><surname>Antikainen</surname><given-names>R</given-names></name><name><surname>Peltonen</surname><given-names>M</given-names></name><name><surname>Laatikainen</surname><given-names>T</given-names></name><name><surname>Barengo</surname><given-names>NC</given-names></name><name><surname>Jula</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Prevalence, awareness and treatment of hypertension in Finland during 1982⊟2007</article-title>. <source>J Hypertens</source> <year>2009</year>; <volume>27</volume>(<issue>8</issue>): <fpage>1552</fpage>–<lpage>1559</lpage>.</citation></ref>
<ref id="bibr11-1741826711410835"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danon-Hersch</surname><given-names>N</given-names></name><name><surname>Marques-Vidal</surname><given-names>P</given-names></name><name><surname>Bovet</surname><given-names>P</given-names></name><name><surname>Chiolero</surname><given-names>A</given-names></name><name><surname>Paccaud</surname><given-names>F</given-names></name><name><surname>Pecoud</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2009</year>; <volume>16</volume>(<issue>1</issue>): <fpage>66</fpage>–<lpage>72</lpage>.</citation></ref>
<ref id="bibr12-1741826711410835"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kearney</surname><given-names>PM</given-names></name><name><surname>Whelton</surname><given-names>M</given-names></name><name><surname>Reynolds</surname><given-names>K</given-names></name><name><surname>Whelton</surname><given-names>PK</given-names></name><name><surname>He</surname><given-names>J</given-names></name></person-group>. <article-title>Worldwide prevalence of hypertension: a systematic review</article-title>. <source>J Hypertens</source> <year>2004</year>; <volume>22</volume>(<issue>1</issue>): <fpage>11</fpage>–<lpage>19</lpage>.</citation></ref>
<ref id="bibr13-1741826711410835"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>M</given-names></name><name><surname>Lunet</surname><given-names>N</given-names></name><name><surname>Azevedo</surname><given-names>A</given-names></name><name><surname>Barros</surname><given-names>H</given-names></name></person-group>. <article-title>Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries</article-title>. <source>J Hypertens</source> <year>2009</year>; <volume>27</volume>(<issue>5</issue>): <fpage>963</fpage>–<lpage>975</lpage>.</citation></ref>
<ref id="bibr14-1741826711410835"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahola</surname><given-names>TL</given-names></name><name><surname>Jula</surname><given-names>AM</given-names></name><name><surname>Kantola</surname><given-names>IM</given-names></name><name><surname>Maki</surname><given-names>J</given-names></name><name><surname>Klaukka</surname><given-names>T</given-names></name><name><surname>Reunanen</surname><given-names>A</given-names></name></person-group>. <article-title>Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult diabetics in Finland. Results from large national database between 2000 and 2006</article-title>. <source>J Hypertens</source> <year>2009</year>; <volume>27</volume>(<issue>11</issue>): <fpage>2283</fpage>–<lpage>2293</lpage>.</citation></ref>
<ref id="bibr15-1741826711410835"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahola</surname><given-names>TL</given-names></name><name><surname>Kantola</surname><given-names>IM</given-names></name><name><surname>Puukka</surname><given-names>P</given-names></name><name><surname>Kattainen</surname><given-names>A</given-names></name><name><surname>Klaukka</surname><given-names>T</given-names></name><name><surname>Reunanen</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult CHD patients in Finland: results from a large national database between 2000 and 2006</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>(<issue>4</issue>): <fpage>477</fpage>–<lpage>485</lpage>.</citation></ref>
<ref id="bibr16-1741826711410835"><label>16</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Koskinen</surname><given-names>S</given-names></name><name><surname>Aromaa</surname><given-names>A</given-names></name></person-group>. <article-title>Health and functional capacity in Finland. Baseline results of the Health 2000 Health Examination Survey</article-title>. <publisher-loc>Helsinki</publisher-loc>: <publisher-name>National Public Health Institute</publisher-name>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.ktl.fi/terveys2000/julkaisut/baseline.pdf">http://www.ktl.fi/terveys2000/julkaisut/baseline.pdf</ext-link> (January 2009)</comment>.</citation></ref>
<ref id="bibr17-1741826711410835"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahlof</surname><given-names>B</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Kjeldsen</surname><given-names>SE</given-names></name><name><surname>Julius</surname><given-names>S</given-names></name><name><surname>Beevers</surname><given-names>G</given-names></name><name><surname>de Faire</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol</article-title>. <source>Lancet</source> <year>2002</year>; <volume>359</volume>(<issue>9311</issue>): <fpage>995</fpage>–<lpage>1003</lpage>.</citation></ref>
<ref id="bibr18-1741826711410835"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>McInnes</surname><given-names>GT</given-names></name><name><surname>Potter</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary</article-title>. <source>BMJ</source> <year>2004</year>; <volume>328</volume>(<issue>7440</issue>): <fpage>634</fpage>–<lpage>640</lpage>.</citation></ref>
<ref id="bibr19-1741826711410835"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agabiti Rosei</surname><given-names>E</given-names></name><name><surname>Rizzoni</surname><given-names>D</given-names></name></person-group>. <article-title>Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics</article-title>. <source>Drugs</source> <year>2007</year>; <volume>67</volume>(<issue>8</issue>): <fpage>1097</fpage>–<lpage>1107</lpage>.</citation></ref>
<ref id="bibr20-1741826711410835"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Galderisi</surname><given-names>M</given-names></name><name><surname>D’Errico</surname><given-names>A</given-names></name><name><surname>Sidiropulos</surname><given-names>M</given-names></name><name><surname>Innelli</surname><given-names>P</given-names></name><name><surname>de Divitiis</surname><given-names>O</given-names></name><name><surname>de Simone</surname><given-names>G</given-names></name></person-group>. <article-title>Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension</article-title>. <source>J Hypertens</source> <year>2009</year>; <volume>27</volume>(<issue>10</issue>): <fpage>2108</fpage>–<lpage>2115</lpage>.</citation></ref>
<ref id="bibr21-1741826711410835"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindholm</surname><given-names>LH</given-names></name><name><surname>Carlberg</surname><given-names>B</given-names></name><name><surname>Samuelsson</surname><given-names>O</given-names></name></person-group>. <article-title>Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis</article-title>. <source>Lancet</source> <year>2005</year>; <volume>366</volume>(<issue>9496</issue>): <fpage>1545</fpage>–<lpage>1553</lpage>.</citation></ref>
<ref id="bibr22-1741826711410835"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Opie</surname><given-names>LH</given-names></name></person-group>. <article-title>Beta-blockade should not be among several choices for initial therapy of hypertension</article-title>. <source>J Hypertens</source> <year>2008</year>; <volume>26</volume>(<issue>2</issue>): <fpage>161</fpage>–<lpage>163</lpage>.</citation></ref>
<ref id="bibr23-1741826711410835"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Messerli</surname><given-names>FH</given-names></name><name><surname>Bangalore</surname><given-names>S</given-names></name><name><surname>Julius</surname><given-names>S</given-names></name></person-group>. <article-title>Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension</article-title>. <source>Circulation</source> <year>2008</year>; <volume>117</volume>(<issue>20</issue>): <fpage>2706</fpage>–<lpage>2715</lpage> <comment>(discussion 2715)</comment>.</citation></ref>
<ref id="bibr24-1741826711410835"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>N</given-names></name><name><surname>McAlister</surname><given-names>FA</given-names></name></person-group>. <article-title>Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis</article-title>. <source>CMAJ</source> <year>2006</year>; <volume>174</volume>(<issue>12</issue>): <fpage>1737</fpage>–<lpage>1742</lpage>.</citation></ref>
<ref id="bibr25-1741826711410835"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>WJ</given-names></name><name><surname>Meyer</surname><given-names>PM</given-names></name></person-group>. <article-title>Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis</article-title>. <source>Lancet</source> <year>2007</year>; <volume>369</volume>(<issue>9557</issue>): <fpage>201</fpage>–<lpage>207</lpage>.</citation></ref>
<ref id="bibr26-1741826711410835"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Grassi</surname><given-names>G</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name></person-group>. <article-title>New-onset diabetes and antihypertensive drugs</article-title>. <source>J Hypertens</source> <year>2006</year>; <volume>24</volume>(<issue>1</issue>): <fpage>3</fpage>–<lpage>10</lpage>.</citation></ref>
<ref id="bibr27-1741826711410835"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bangalore</surname><given-names>S</given-names></name><name><surname>Parkar</surname><given-names>S</given-names></name><name><surname>Grossman</surname><given-names>E</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name></person-group>. <article-title>A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus</article-title>. <source>Am J Cardiol</source> <year>2007</year>; <volume>100</volume>(<issue>8</issue>): <fpage>1254</fpage>–<lpage>1262</lpage>.</citation></ref>
<ref id="bibr28-1741826711410835"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manolis</surname><given-names>A</given-names></name><name><surname>Doumas</surname><given-names>M</given-names></name></person-group>. <article-title>Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications</article-title>. <source>J Hypertens</source> <year>2008</year>; <volume>26</volume>(<issue>11</issue>): <fpage>2074</fpage>–<lpage>2084</lpage>.</citation></ref>
<ref id="bibr29-1741826711410835"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sever</surname><given-names>PS</given-names></name><name><surname>Dahlof</surname><given-names>B</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name><name><surname>Beevers</surname><given-names>G</given-names></name><name><surname>Caulfield</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial − Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial</article-title>. <source>Lancet</source> <year>2003</year>; <volume>361</volume>(<issue>9364</issue>): <fpage>1149</fpage>–<lpage>1158</lpage>.</citation></ref>
</ref-list>
</back>
</article>